BlackRock’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

BlackRock’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,799,818	Closed	-$300M	–	5655
2023 Q1	$300M	Sell	2,799,818 -7,886	-0.3%	-$908K	0.01%	1265
2022 Q4	$309M	Buy	2,807,704 +673,432	+32%	+$43.7M	0.01%	1220
2022 Q3	$126M	Buy	2,134,272 +319,310	+18%	+$14.6M	﹤0.01%	1811
2022 Q2	$51.2M	Sell	1,814,962 -343,989	-16%	-$9.97M	﹤0.01%	2483
2022 Q1	$81.5M	Sell	2,158,951 -1,818	-0.1%	-$71.9K	﹤0.01%	2267
2021 Q4	$85.4M	Buy	2,160,769 +1,220,649	+130%	+$38.2M	﹤0.01%	2313
2021 Q3	$22.3M	Buy	940,120 +942	+0.1%	+$22.2K	﹤0.01%	3211
2021 Q2	$23.1M	Buy	939,178 +593,261	+172%	+$13.2M	﹤0.01%	3214
2021 Q1	$6.32M	Buy	+345,917	New	+$7.14M	﹤0.01%	3831

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

BlackRock's RXDX Position: Q2 2023 in Review

BlackRock sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,799,818 shares — an estimated $300M sold.

BlackRock first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $309M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

BlackRock reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
BlackRock sold 2,799,818 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $300M.
BlackRock first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
BlackRock's Prometheus Biosciences, Inc. Common Stock position peaked at $309M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.